Literature DB >> 24771611

A protease storm cleaves a cell-cell adhesion molecule in cancer: multiple proteases converge to regulate PTPmu in glioma cells.

Polly J Phillips-Mason1, Sonya E L Craig, Susann M Brady-Kalnay.   

Abstract

Cleavage of the cell-cell adhesion molecule, PTPµ, occurs in human glioblastoma multiforme brain tumor tissue and glioma cell lines. PTPµ cleavage is linked to increased cell motility and growth factor independent survival of glioma cells in vitro. Previously, PTPµ was shown to be cleaved by furin in the endoplasmic reticulum to generate membrane associated E- (extracellular) and P- (phosphatase) subunits, and by ADAMs and the gamma secretase complex at the plasma membrane. We also identified the presence of additional extracellular and intracellular PTPµ fragments in brain tumors. We set out to biochemically analyze PTPµ cleavage in cancer cells. We determined that, in addition to the furin-processed form of PTPµ, a pool of 200 kDa full-length PTPµ exists at the plasma membrane that is cleaved directly by ADAM to generate a larger shed form of the PTPµ extracellular segment. Notably, in glioma cells, full-length PTPµ is also subject to calpain cleavage, which generates novel PTPµ fragments not found in other immortalized cells. We also observed glycosylation and phosphorylation differences in the cancer cells. Our data suggest that an additional serine protease also contributes to PTPµ shedding in glioma cells. We hypothesize that a "protease storm" occurs in cancer cells whereby multiple proteases converge to reduce the presence of cell-cell adhesion molecules at the plasma membrane and to generate protein fragments with unique biological functions. As a consequence, the "protease storm" could promote the migration and invasion of tumor cells.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  PROTEOLYSIS; SHEDDING; PTPmu; RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; ADAM; CALPAIN; FURIN; SERINE PROTEASE; GLIOMA

Mesh:

Substances:

Year:  2014        PMID: 24771611      PMCID: PMC4600327          DOI: 10.1002/jcb.24824

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  49 in total

1.  Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2.

Authors:  Hyo Sang Jang; Sangeet Lal; Jeffrey A Greenwood
Journal:  Neurochem Res       Date:  2010-08-21       Impact factor: 3.996

2.  A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu.

Authors:  Susan M Burden-Gulley; Theresa J Gates; Adam M Burgoyne; Jennifer L Cutter; David T Lodowski; Shenandoah Robinson; Andrew E Sloan; Robert H Miller; James P Basilion; Susann M Brady-Kalnay
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

Review 3.  Tumor-derived extracellular fragments of receptor protein tyrosine phosphatases (RPTPs) as cancer molecular diagnostic tools.

Authors:  Sonya E L Craig; Susann M Brady-Kalnay
Journal:  Anticancer Agents Med Chem       Date:  2011-01       Impact factor: 2.505

4.  Epidermal growth factor (EGF) ligand release by substrate-specific a disintegrin and metalloproteases (ADAMs) involves different protein kinase C (PKC) isoenzymes depending on the stimulus.

Authors:  Michelle Dang; Karen Dubbin; Antonio D'Aiello; Monika Hartmann; Harvey Lodish; Andreas Herrlich
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

5.  Cancer cells cut homophilic cell adhesion molecules and run.

Authors:  Sonya E L Craig; Susann M Brady-Kalnay
Journal:  Cancer Res       Date:  2010-11-17       Impact factor: 12.701

Review 6.  The calpain system and cancer.

Authors:  Sarah J Storr; Neil O Carragher; Margaret C Frame; Tim Parr; Stewart G Martin
Journal:  Nat Rev Cancer       Date:  2011-05       Impact factor: 60.716

7.  Should I stay or should I go? Shedding of RPTPs in cancer cells switches signals from stabilizing cell-cell adhesion to driving cell migration.

Authors:  Polly J Phillips-Mason; Sonya E L Craig; Susann M Brady-Kalnay
Journal:  Cell Adh Migr       Date:  2011-07-01       Impact factor: 3.405

Review 8.  Calpains as potential anti-cancer targets.

Authors:  Ludovic Leloup; Alan Wells
Journal:  Expert Opin Ther Targets       Date:  2011-01-19       Impact factor: 6.902

9.  Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration.

Authors:  Adam M Burgoyne; Polly J Phillips-Mason; Susan M Burden-Gulley; Shenandoah Robinson; Andrew E Sloan; Robert H Miller; Susann M Brady-Kalnay
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

10.  PTPmu suppresses glioma cell migration and dispersal.

Authors:  Adam M Burgoyne; Juan M Palomo; Polly J Phillips-Mason; Susan M Burden-Gulley; Denice L Major; Anita Zaremba; Shenandoah Robinson; Andrew E Sloan; Michael A Vogelbaum; Robert H Miller; Susann M Brady-Kalnay
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more
  9 in total

1.  PTPmu-targeted nanoparticles label invasive pediatric and adult glioblastoma.

Authors:  Gil Covarrubias; Mette L Johansen; Jason Vincent; Bernadette O Erokwu; Sonya E L Craig; Abdelrahman Rahmy; Anthony Cha; Morgan Lorkowski; Christina MacAskill; Bryan Scott; Madhusudhana Gargesha; Debashish Roy; Chris A Flask; Efstathios Karathanasis; Susann M Brady-Kalnay
Journal:  Nanomedicine       Date:  2020-05-13       Impact factor: 5.307

Review 2.  Regulation of development and cancer by the R2B subfamily of RPTPs and the implications of proteolysis.

Authors:  Sonya E L Craig; Susann M Brady-Kalnay
Journal:  Semin Cell Dev Biol       Date:  2014-09-16       Impact factor: 7.727

3.  Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts.

Authors:  Jason Vincent; Sonya E L Craig; Mette L Johansen; Jyosthna Narla; Stefanie Avril; Analisa DiFeo; Susann M Brady-Kalnay
Journal:  Diagnostics (Basel)       Date:  2021-01-27

Review 4.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

Review 5.  Genetic alterations of protein tyrosine phosphatases in human cancers.

Authors:  S Zhao; D Sedwick; Z Wang
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Current Challenges and Opportunities in Treating Glioblastoma.

Authors:  Andrea Shergalis; Armand Bankhead; Urarika Luesakul; Nongnuj Muangsin; Nouri Neamati
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

7.  A PTPmu Biomarker is Associated with Increased Survival in Gliomas.

Authors:  Mette L Johansen; Jason Vincent; Haley Gittleman; Sonya E L Craig; Marta Couce; Andrew E Sloan; Jill S Barnholtz-Sloan; Susann M Brady-Kalnay
Journal:  Int J Mol Sci       Date:  2019-05-14       Impact factor: 5.923

8.  SLPI is a critical mediator that controls PTH-induced bone formation.

Authors:  Akito Morimoto; Junichi Kikuta; Keizo Nishikawa; Takao Sudo; Maki Uenaka; Masayuki Furuya; Tetsuo Hasegawa; Kunihiko Hashimoto; Hiroyuki Tsukazaki; Shigeto Seno; Akira Nakamura; Daisuke Okuzaki; Fuminori Sugihara; Akinori Ninomiya; Takeshi Yoshimura; Ryoko Takao-Kawabata; Hideo Matsuda; Masaru Ishii
Journal:  Nat Commun       Date:  2021-04-09       Impact factor: 14.919

9.  NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.

Authors:  Naze G Avci; Sadaf Ebrahimzadeh-Pustchi; Yasemin M Akay; Yoshua Esquenazi; Nitin Tandon; Jay-Jiguang Zhu; Metin Akay
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.